Sector News

Boehringer trims Connecticut workforce as sales suffer

February 17, 2015
Life sciences
Struggling with falling sales, Boehringer Ingelheim is trimming its workforce in Connecticut, which accounts for about 2,700 staffers altogether. 
 
A company spokesperson tells FierceBiotech that less than 5% of its staff at the Ridgefield site is affected by the move, or 2% of the total, but the company is looking to find new positions for some of the people involved in the cutback. 
 
“Boehringer Ingelheim is in the process of rebalancing its workforce in the U.S. to put the company in the best position for future growth,” the company says in a statement. 
 
The 294-acre Ridgefield campus is the site of one of three major R&D centers for Boehringer and serves as its U.S. headquarters. Boehringer announced plans for a $65 million facility to support R&D and production back in 2011.
 
Just weeks ago the company reviewed a possible move to sell its $2.3 billion generics unit and a facility in Columbus, OH. Last fall Boehringer also said it would trim hundreds of jobs in Germany to account for a 5% drop in sales and a reduced forecast for the second half of the year.
 
By John Carroll
 

Related News

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]

September 15, 2020

Gilead to buy Immunomedics for $21bn

Life sciences

Gilead Sciences has announced plans to acquire Immunomedics in a deal valued at $21 billion. Under the agreement, which has been unanimously approved by both boards of directors, Gilead will […]